Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
CHRNA6 overexpression
Cancer:
Lung Cancer
Drug Class:
Immunotherapy
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Curr Pharm Des
Title:
Involvement of CHRNA6 in the Immune Response in Lung Squamous Cell Carcinoma and its Potential as a Drug Target for the Disease
Published date:
09/08/2023
Excerpt:
In addition, LUSC patients with higher CHRNA6 expression levels had better immunotherapy responses.
DOI:
10.2174/1381612829666230901143203
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.